Machine learning of brain-behavior dimensions reveals four subtypes of autism spectrum disorder linked to distinct molecular pathways. Here, the 3D prism cube represents the machine learning of the three brain-behavior dimensions, etched onto the prism's glass. White light or “data” passes into the prism or "machine learning algorithm," splitting into four colored light paths that represent the spectrum of autistic people in the four autism subtypes. The painted background of a sequencing array represents the molecular associations of the autism subtypes. Credit: Dr. Amanda Buch
Machine learning of brain-behavior dimensions reveals four subtypes of autism spectrum disorder linked to distinct molecular pathways. Here, the 3D prism cube represents the machine learning of the three brain-behavior dimensions, etched onto the prism's glass. White light or “data” passes into the prism or "machine learning algorithm," splitting into four colored light paths that represent the spectrum of autistic people in the four autism subtypes. The painted background of a sequencing array represents the molecular associations of the autism subtypes. Credit: Dr. Amanda Buch

Weill Cornell Medicine leverages ML to identify four different autism subtypes

People with autism spectrum disorder can be classified into four distinct subtypes based on their brain activity and behavior, according to a study from Weill Cornell Medicine investigators in New York City.

The study leveraged machine learning to analyze newly available neuroimaging data from 299 people with autism and 907 neurotypical people. They found patterns of brain connections linked with behavioral traits in people with autism, such as verbal ability, social effect, and repetitive or stereotypic behaviors. They confirmed that the four autism subgroups could also be replicated in a separate dataset and showed that differences in regional gene expression and protein-protein interactions explain the brain and behavioral differences.

“Like many neuropsychiatric diagnoses, individuals with autism spectrum disorder experience many different types of difficulties with social interaction, communication, and repetitive behaviors. Scientists believe there are probably many different types of autism spectrum disorder that might require different treatments, but there is no consensus on how to define them,” said co-senior author Dr. Conor Liston, an associate professor of psychiatry and of neuroscience in the Feil Family Brain and Mind Research Institute at Weill Cornell Medicine. “Our work highlights a new approach to discovering subtypes of autism that might one day lead to new approaches for diagnosis and treatment.”

A previous study published by Dr. Liston and colleagues in Nature Medicine in 2017 used similar machine-learning methods to identify four biologically distinct subtypes of depression, and subsequent work has shown that those subgroups respond differently to various depression therapies.

“If you put people with depression in the right group, you can assign them the best therapy,” said lead author Dr. Amanda Buch, a postdoctoral associate of neuroscience in psychiatry at Weill Cornell Medicine.

Building on that success, the team set out to determine if similar subgroups exist among individuals with autism, and whether different gene pathways underlie them. She explained that autism is a highly heritable condition associated with hundreds of genes that have diverse presentations and limited therapeutic options. To investigate this, Dr. Buch pioneered new analyses for integrating neuroimaging data with gene expression data and proteomics, introducing them to the lab and enabling testing and developing hypotheses about how risk variants interact in the autism subgroups.

“One of the barriers to developing therapies for autism is that the diagnostic criteria are broad, and thus apply to a large and phenotypically diverse group of people with different underlying biological mechanisms,” Dr. Buch said. “To personalize therapies for individuals with autism, it will be important to understand and target this biological diversity. It is hard to identify the optimal therapy when everyone is treated as being the same when they are each unique.”

Until recently, there were not large enough collections of functional magnetic resonance imaging data of people with autism to conduct large-scale machine learning studies, Dr. Buch noted. But a large dataset created and shared by Dr. Adriana Di Martino, research director of the Autism Center at the Child Mind Institute, as well as other colleagues across the country, provided the large dataset needed for the study.

“New methods of machine learning that can deal with thousands of genes, brain activity differences, and multiple behavioral variations made the study possible,” said co-senior author Dr. Logan Grosenick, an assistant professor of neuroscience in psychiatry at Weill Cornell Medicine, who pioneered machine-learning techniques used for biological subtyping in the autism and depression studies.

Those advances allowed the team to identify four clinically distinct groups of people with autism. Two of the groups had above-average verbal intelligence. One group also had severe deficits in social communication but less repetitive behaviors, while the other had more repetitive behaviors and less social impairment. The connections between the parts of the brain that process visual information and help the brain identify the most salient incoming information were hyperactive in the subgroup with more social impairment. These same connections were weak in the group with more repetitive behaviors.

“It was interesting on a brain circuit level that there were similar brain networks implicated in both of these subtypes, but the connections in these same networks were atypical in opposite directions,” said Dr. Buch, who completed her doctorate from Weill Cornell Graduate School of Medical Sciences in Dr. Liston’s lab and is now working in Dr. Grosenick’s lab. 

The other two groups had severe social impairments and repetitive behaviors but had verbal abilities at the opposite ends of the spectrum. Despite some behavioral similarities, the investigators discovered completely distinct brain connection patterns in these two subgroups.

The team analyzed gene expression that explained the atypical brain connections present in each subgroup to better understand what was causing the differences and found many were genes previously linked with autism. They also analyzed network interactions between proteins associated with the atypical brain connections, and looked for proteins that might serve as a hub. Oxytocin, a protein previously linked with positive social interactions, was a hub protein in the subgroup of individuals with more social impairment but relatively limited repetitive behaviors. Studies have looked at using intranasal oxytocin as a therapy for people with autism with mixed results, Dr. Buch said. She said it would be interesting to test whether oxytocin therapy is more effective in this subgroup.

“You could have treatment that is working in a subgroup of people with autism, but that benefit washes out in the larger trial because you are not paying attention to subgroups,” Dr. Grosenick said.

The team confirmed their results on a second human dataset, finding the same four subgroups. As a final verification of the team’s results, Dr. Buch conducted an unbiased text-mining analysis she developed of biomedical literature that showed other studies had independently connected the autism-linked genes with the same behavioral traits associated with the subgroups.

The team will next study these subgroups and potential subgroup-targeted treatments in mice. Collaborations with several other research teams with large human datasets are also underway. The team is also working to refine their machine-learning techniques further.

“We are trying to make our machine learning more cluster-aware,” Dr. Grosenick said.

In the meantime, Dr. Buch said they’ve received encouraging feedback from individuals with autism about their work. One neuroscientist with autism spoke to Dr. Buch after a presentation and said his diagnosis was confusing because his autism was so different than others but that her data helped explain his experience.

“Being diagnosed with a subtype of autism could have been helpful for him,” Dr. Buch said.    

Shirin Nilizadeh
Shirin Nilizadeh

UT Arlington researcher aims to improve online safeguards that protect user privacy

A University of Texas at Arlington computer security researcher has received a prestigious federal grant to determine what technologies and methods work best to attain and retain online security and privacy.

Shirin Nilizadeh, assistant professor in the Department of Computer Science and Engineering, received a $200,000 National Science Foundation grant to study social media discussions and better understand what concerns are about online security and privacy, what technologies and tools they suggest to each other to use and whether they are effective. Nilizadeh called this a “worldwide challenge.”

“People care about their online security and privacy everywhere,” she said. “And sometimes, due to societal and political movements, they become more cautious or aware of the problems, where they go online and on social media, and proactively discuss their concerns and ask for tools and methods that can help protect them.

“We can help as a research community to see what’s working and what isn’t. We can take these research findings to design and develop better online safeguards and to improve the existing security and privacy-preserving systems if they are not secure, effective, and efficient.”

Hong Jiang, chair of the Department of Computer Science and Engineering, said Nilizadeh’s research could further the security of social network tools.

“Everyone is connected to social networks,” Jiang said. “Studying social networks’ discussions and understanding what security measures people are looking for and using allow researchers  to develop and provide such measures to improve online security and privacy.”

Previous Nilizadeh's work showed that social media users extensively discussed the security and privacy threats of video communication tools more people started working from home due to the COVID-19 pandemic. This work showed how misinformation about security and privacy spread on social media platforms.

Nilizadeh previously did work on how job applicants can “hack” hiring systems and improve their standing by using certain words on their applications. She also has studied whether security and privacy applications like content moderation tools are fair toward users from various demographics and backgrounds.

Brown-built model shows how non-drug interventions for patients with Alzheimer’s are both effective, economical

A Brown-led research team used a supercomputer simulation to show that compared to usual care, four dementia-care interventions saved up to $13,000 in costs, reduced nursing home admissions, and improved quality of life.

While new drugs to treat Alzheimer’s disease tend to receive the most public attention, many well-researched ways to care for people with dementia don’t involve medication. A new evaluation compared the cost-effectiveness of four non-drug interventions to the usual care received by people with dementia and found that the interventions not only resulted in a better quality of life but also saved money.

In a study published April 6 in Alzheimer's & Dementia: The Journal of the Alzheimer's Association, researchers used a supercomputer simulation model to show that the four dementia-care interventions saved between $2,800 and $13,000 in societal costs, depending on the type of intervention, and all reduced nursing home admissions and improved quality of life compared to usual care.

Alzheimer’s drugs hold great promise, but they still need additional research and improvement, said lead study author Eric Jutkowitz, an associate professor at Brown University’s School of Public Health. In the meantime, he said, several non-drug interventions are effective in clinical trials in improving the quality of life for people with dementia and helping them stay safe at home longer.

“Now that we can show that these effective interventions can also save money, it just makes sense to find ways to make them available to more families,” Jutkowitz said. “These interventions can be used to help people with dementia starting today.”

The four interventions studied included the following: Maximizing Independence at Home, an at-home, care coordination intervention that consists of care planning, skill-building, referrals to services, and careful monitoring; New York University Caregiver, which is implemented in an outpatient clinic and provides caregivers with six counseling sessions over four months plus lifetime ad-hoc support and access to weekly support groups; Alzheimer’s and Dementia Care, in which a health care system provides people living with dementia and their caregivers a needs assessment, individual care plans and round-the-clock access to a care manager; and Adult Day Service Plus, which augments adult day care services with staff providing face-to-face caregiver support, disease education, care management, skill-building, and resource referrals.

Nonpharmacological interventions like these provide family caregivers with knowledge, skills, and support tailored to their care challenges. They have been shown to improve the quality of life for the caregiver and the person living with dementia, as well as to reduce nursing home admissions, and they are not associated with adverse events such as hospitalizations and mortality. For these reasons, nonpharmacological interventions are recommended as first-line therapies for the management of Alzheimer’s and dementia.

While non-drug interventions are well-studied, Jutkowitz said they haven't been widely implemented in clinical care centers. He added that there isn’t currently an infrastructure in place to support these methods of care — for example, there are limited mechanisms for providers to be reimbursed for these types of interventions.

To conduct the study, the researchers used a supercomputer simulation to model the likelihood of nursing home admission for four evidence-based Alzheimer’s and dementia nonpharmacological interventions compared to usual care. For each, the study evaluated societal costs, quality-adjusted life-years, and cost-effectiveness. The inputs in the simulation were based on data from Medicare, clinical trials, and national surveys with families of people with dementia.

Jutkowitz noted that the researchers benefited not only from Brown University supercomputing resources that could handle intensive analytic tasks but also access to data from the government’s Centers for Medicare and Medicaid Services, which was crucial to the analysis.

In addition to finding that the interventions were cost-effective from a societal perspective, the researchers also found that from a healthcare payer perspective, the interventions involved little to no additional cost, compared to usual care, while increasing patient quality of life.

Based on the study findings, the authors concluded that health insurance policies should find ways to incentivize providers and health systems to implement nonpharmacological interventions.

The importance of understanding the cost-effectiveness of non-drug Alzheimer’s and dementia interventions is further highlighted by changes in Medicare payment models and emerging Alzheimer’s therapeutics, the researchers noted. The Centers for Medicare and Medicaid Services is in the process of determining coverage for new Alzheimer’s and related dementia drugs.

“As the Centers for Medicare and Medicaid Services determine coverage for new Alzheimer’s and related dementia drugs, we strongly believe that CMS should also consider the benefits of nonpharmacologic interventions,” Jutkowitz said.

While this study focused on non-drug interventions that reduce nursing home admissions, a future analysis will look at similar interventions that reduce or maintain functional decline and challenging behaviors. The researchers are also working on designing a trial that would test the interventions with patients in a healthcare setting.

Additional Brown contributors included Peter Shewmaker and Gary Epstein-Lubow.

This research was supported by the National Institute on Aging (1R21AG059623-01, 1R01AG060871-01, 1RF1AG069771, R01AG049692).

Tokyo Tech deploys database online aimed at boosting drug design using cyclic peptides

CycPeptMPDB, a novel database created by Tokyo Tech researchers focused on the membrane permeability of cyclic peptides, could accelerate the development of drugs based on these promising compounds. This database was created by gathering published information on thousands of cyclic peptides and organizing it neatly in an online-accessible platform. Thanks to its search and visualization capabilities, CycPeptMPDB could pave the way to new super-computational machine-learning methods for screening and designing drugs with cyclic peptides.

One of the greatest challenges in modern drug design is to find compounds that satisfy somewhat contradictory requirements—they need to be small enough to permeate human cell membranes while being large enough to target various protein surfaces and protein–protein interactions. This is a fine balance to achieve—if the compounds are too large, they may not pass through the cell membrane, and their bioavailability would be affected; if they are too small, they would not retain high specificity to the target protein (or proteins).  Scientists estimate that over 80% of all known proteins associated with diseases cannot be targeted by conventional small-molecule drugs or antibody-based drugs. That is why, in recent years, cyclic peptides have become a very active research area. In principle, these compounds can achieve the fine balance required of modern drugs.

A cyclic peptide is a type of organic molecule that consists of amino acids linked together in a circular or lariat shape. What makes them particularly attractive is that they can target intracellular protein–protein interactions, which have been considered “undruggable” for decades. Moreover, cyclic peptides are inexpensive to synthesize compared to antibody-based drugs, prompting many pharmaceutical companies to conduct extensive research on these compounds.

However, one of the biggest hurdles to overcome in cyclic peptide research is that their membrane permeability—which controls their bioavailability and efficiency as drugs—is low in general, and the mechanisms behind this are not completely understood. Thus, during drug design, it is difficult for researchers to select candidate peptides that are likely to make it through the cell membrane. On top of this, there are currently no openly accessible databases documenting the membrane permeabilities of known cyclic peptides.

Against this backdrop, a team of researchers from the Tokyo Institute of Technology (Tokyo Tech), Japan, including Professor Yutaka Akiyama, decided to take a step towards making cyclic peptide research easier for everyone. As explained in their latest paper published in the Journal of Chemical Information and Modeling, the team created an online database called CycPeptMPDB that contains information on thousands of cyclic peptides, including their membrane permeability.

To build the database, they gathered data from previously published papers and pharmaceutical patents. After inspecting over 40 publications, they collected information on 7,334 cyclic peptides with widely different chemical structures. They loaded the membrane permeability values and important physical parameters such as the lipophilicity of these peptides onto the database.

Moreover, to make further analysis and visualization of the molecules possible, the researchers calculated the most likely 3D conformation of each peptide and added it to the database. They also encoded the chemical structure of each cyclic peptide in a novel descriptive notation (called HELM), making it possible to unambiguously refer to any cyclic peptide in the database using a short string of text.

The team has high hopes for its platform and believes that it could become a game changer in the design and development of cyclic peptide drugs. “CycPeptMPDB provides several functions, including data storage, statistics and visualization, searching and analysis, and downloading. We expect it will become a valuable tool to support membrane permeability research on cyclic peptides,” remarks Prof. Akiyama. It is also worth noting, that databases such as CycPeptMPDB are essential for training machine learning models, which can accelerate the selection of drug candidates and reveal hidden patterns in the data.

“We will continue to collect membrane permeability data of cyclic peptides and record them in CycPeptMPDB. Additionally, future improvements to the database’s online analysis platform will include an improved user-friendly interface and more integrative functions,” comments Prof. Akiyama.

A new Smidt Heart Institute study published in Nature showed  that artificial intelligence was expert in assessing and diagnosing cardiac function by analyzing echocardiogram images. Image by Getty.
A new Smidt Heart Institute study published in Nature showed that artificial intelligence was expert in assessing and diagnosing cardiac function by analyzing echocardiogram images. Image by Getty.

Cedars-Sinai cardiologist Ouyang investigates the performance of AI at assessing heart health

Published in Nature, new research from the Smidt Heart Institute shows whether artificial intelligence or sonographers provide the most accurate heart evaluations

Who can assess and diagnose cardiac function best after reading an echocardiogram: artificial intelligence (AI) or a sonographer? 

According to Cedars-Sinai investigators and their research published today in the academic journal Nature, AI proved superior in assessing and diagnosing cardiac function when compared with echocardiogram assessments made by sonographers.  

The findings are based on a first-of-its-kind, blinded, randomized clinical trial of AI in cardiology led by investigators in the Smidt Heart Institute and the Division of Artificial Intelligence in Medicine at Cedars-Sinai. 

“The results have immediate implications for patients undergoing cardiac function imaging as well as broader implications for the field of cardiac imaging,” said cardiologist David Ouyang, MD, principal investigator of the clinical trial and senior author of the study. “This trial offers rigorous evidence that utilizing AI in this novel way can improve the quality and effectiveness of echocardiogram imaging for many patients.” David Ouyang, MD

Investigators are confident that this technology will be found beneficial when deployed across the clinical system at Cedars-Sinai and health systems nationwide.

“This successful clinical trial sets a superb precedent for how novel clinical AI algorithms can be discovered and tested within health systems, increasing the likelihood of seamless deployment for improved patient care,” said Sumeet Chugh, MD, director of the Division of Artificial Intelligence in Medicine and the Pauline and Harold Price Chair in Cardiac Electrophysiology Research.

In 2020, researchers at the Smidt Heart Institute and Stanford University developed one of the first AI technologies to assess cardiac function, specifically, left ventricular ejection fraction—the key heart measurement used in diagnosing cardiac function. Their research also was published in Nature.

Building on those findings, the new study assessed whether AI was more accurate in evaluating 3,495 transthoracic echocardiogram studies by comparing initial assessment by AI or by a sonographer—also known as an ultrasound technician.

Among the findings: 

  • Cardiologists more frequently agreed with the AI initial assessment and made corrections to only 16.8% of the initial assessments made by AI. 
  • Cardiologists made corrections to 27.2% of the initial assessments made by the sonographers. 
  • The physicians were unable to tell which assessments were made by AI and which were made by sonographers.
  • The AI assistance saved cardiologists and sonographers time.

“We asked our cardiologists to guess if the preliminary interpretation was performed by AI or by a sonographer, and it turns out that they couldn’t tell the difference,” said Ouyang. “This speaks to the strong performance of the AI algorithm as well as the seamless integration into clinical software. We believe these are all good signs for future AI trial research in the field.”

The hope, Ouyang says, is to save clinicians time and minimize the more tedious parts of the cardiac imaging workflow. The cardiologist, however, remains the final expert adjudicator of the AI model output. 

The clinical trial and subsequent published research also shed light on the opportunity for regulatory approvals.

“This work raises the bar for artificial intelligence technologies being considered for regulatory approval, as the Food and Drug Administration has previously approved artificial intelligence tools without data from prospective clinical trials,” said Susan Cheng, MD, MPH, director of the Institute for Research on Healthy Aging in the Department of Cardiology at the Smidt Heart Institute and co-senior author of the study. “We believe this level of evidence offers clinicians extra assurance as health systems work to adopt artificial intelligence more broadly as part of efforts to increase efficiency and quality overall.”